Botulinum toxin type B (Myobloc™, Neurobloc™): A new choice in cervical dystonia

Expert Review of Neurotherapeutics

Volumn 1, Issue 2, 2001, Pages 143-152

  Lew, Mark F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acetylcholine blockade; Botulinum toxin type B; Cervical dystonia; Chemical denervation; Myobloc; NeuroBloc; Neuromascular blocking agent; Neuromascular disorder; Neurotoxin; Spasmodic torticollis

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROMUSCULAR BLOCKING AGENT; NEUROTOXIN; SYNAPTOBREVIN;

CERVICAL DYSTONIA; DENERVATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DYSPEPSIA; DYSPHAGIA; DYSTONIA; ELECTROPHYSIOLOGY; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; INJECTION SITE; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PAIN; PARALYSIS; PRESYNAPTIC NERVE; REVIEW; SPASMODIC TORTICOLLIS; SPASTICITY; XEROSTOMIA;

EID: 0035741356     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.2.143     Document Type: Review

References (68)

1. Epidemiology of dystonia in Rochester, Minnesota
2. Spasmodic torticollis - Review of 220 patients
3. Idiopathic cervical dystonia: Clinical characteristics
4. Pain in spasmodic totticollis
5. Pain perception in idiopathic cervical dystonia (spasmodic torricollis)
6. Psychological functioning before and after treatment of torticollis with botulinum toxin
7. Psychosocial factors and depression in torticollis
8. Systemic therapy for dystonia
9. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs
10. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia
11. Selective peripheral denervation for spasmodic torticollis: Surgical technique, results and observations in 260 cases
12. Outcome of selective ramisectomy for botulinum toxin resistant torticollis
13. Symptomatic and functional outcome of surgical treatment of cervical dystonia
14. Idiosyncratic adverse reactions to im. botulinum, toxin type A injection
15. Local treatment of spasmodic torticollis with botulinum toxin
16. Therapeutic uses of botulinum toxin
17. Medical therapy and botulinum toxin in dystonia
18. The current use of botulinum toxin
19. Botulinum toxin as a biological weapon
20. Botulinum neurotoxin serotype C: A novel effect botulinum toxin in human
21. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
22. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A
23. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study
24. Botulinum toxin therapy, immunologic resistance and problems with available materials
25. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections
26. Development of resistance to botulinum toxin type A patients with torticollis
27. Response and immunoresistance to botulinum toxin injections
28. The biochemistry of botulinum toxin type B
29. Clinical correlates of response to botulinum toxin injections
30. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance
31. Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations
32. Distant effects of locally injected botulinum toxin: A double-blind study of single fiber EMG changes
33. Neuromuscular effects distant from the site of botulinum neurotoxin injection
34. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases
35. Clostridium botulinum toxins
36. Clostridium botulinum neurotoxin
37. Preparation and properties of botulinum toxin for medical use
38. Quality of botulinum toxin for human treatment
39. Structure and function of tetanus and botulinum neurotoxins
40. Disulfide-toxicity relationship of botulinal toxin types A, E and E
41. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin
42. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum
43. Isolated light chains of botulinum neurotoxins inhibit exocytosis: Studies in digitonin-permeabilized chromaffin cells
44. Clostridial neurotoxins: Handling and action at the cellular and molecular level
45. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction
46. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
47. Molecular aspects of tetanus and botulinum neurotoxin poisoning
48. Secrets of secretion revealed
49. Botulinum toxin type B: An overview of its biochemistry and preclinical pharmacology
50. Botulinum toxin type B: Experimental and clinical experience
51. Effects of im. injection of botulinum toxin type B in nonhuman primates
52. Clinical spectrum of botulism
53. The effects of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model
54. A comparative systemic toxicity study of Neurobloc™ in adult and juvenile cynomolgus monkeys
55. Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type A-responsive cervical dystonia
56. Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type A-resistant cervical dystonia
57. Botulinum toxin type B: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients
58. Bot B (botulinum toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)
59. Botulinum toxin type B in the treatment of cervical dystonia: A pilot study
60. BotB (botulinum toxin type B) in the treatment of cervical dystonia. (CD) - protocol AN072-008: An interim analysis
61. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
62. Safety and effectiveness of Neurobloc (botulinum toxin type B solution): An open-label, dose-escalation study
63. Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance
64. Swallowing function in patients with torticollis
65. Clinical use of botulinum toxin